ArticleNeoplasia (New York, N.Y.)2008
RAS signaling in colorectal carcinomas through alteration of RAS, RAF, NF1, and/or RASSF1A.
Article in Neoplasia (New York, N.Y.), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Unraveling the prevalence of various signalling pathways in non-small-cell lung cancer: a review.Molecular and cellular biochemistry · 2023Review
- Article
- Identification of key candidate genes and pathways associated with colorectal aberrant crypt foci-to-adenoma-to-carcinoma progression.Gastroenterology and hepatology from bed to bench · 2021Article
- Downregulation ofInternational journal of molecular sciences · 2020Article
- Overexpression of ST5, an activator of Ras, has no effect on β-cell proliferation in adult mice.Molecular metabolism · 2018Article
- Association between clinicopathological characteristics and RAS mutation in colorectal cancer.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2018Observational
- A robust targeted sequencing approach for low input and variable quality DNA from clinical samples.NPJ genomic medicine · 2018Article
- Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors.Molecular oncology · 2017Article
- The NF1 somatic mutational landscape in sporadic human cancers.Human genomics · 2017Review
- Methylation status of theOncology letters · 2016Article
- An Unusual Combination: KRAS and BRAF Co-mutated Metastatic Colorectal Cancer.Journal of gastrointestinal cancer · 2016Article
- MicroRNA Expression Signatures Associated With BRAF-Mutated Versus KRAS-Mutated Colorectal Cancers.Medicine · 2016Observational
- Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance.Oncotarget · 2015Review
- Article
- Article
- The NF1 gene revisited - from bench to bedside.Oncotarget · 2014Review
- Influence of microsatellite instability and KRAS and BRAF mutations on lymph node harvest in stage I-III colon cancers.Molecular medicine (Cambridge, Mass.) · 2013Article
- Article
- RAS signaling pathways, mutations and their role in colorectal cancer.World journal of gastrointestinal oncology · 2013Article
- Loss of RASSF1A expression in colorectal cancer and its association with K-ras status.BioMed research international · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
More than half of all colorectal carcinomas are known to exhibit an activated mitogen-activated protein kinase pathway. The NF1 gene, a negative regulator of KRAS, has not previously been examined in a series of colorectal cancer. In the present study, primary colorectal carcinomas stratified according to microsatellite instability status were analyzed. The whole coding region of NF1 was analyzed for mutations using denaturing high-performance liquid chromatography and sequencing, and the copy number alterations of NF1 were examined using multiple ligation-dependent probe amplification and real-time polymerase chain reaction. The mutational hot spots in KRAS and BRAF were sequenced, and promoter hypermethylation status of RASSF1A was assessed with a methylation-specific polymerase chain reaction. One sample had two missense mutations in NF1, whereas nine additional tumors had intronic mutations likely to affect exon splicing. Interestingly, 8 of these 10 tumors were microsatellite-unstable. Four other tumors showed a duplication of NF1. Mutations in KRAS and BRAF were mutually exclusive and were present at 40% and 22%, respectively. RASSF1A was hypermethylated in 31% of the samples. We show that the RAS signaling network is extensively dysregulated in colorectal carcinomas, because more than 70% of the tumors had an alteration in one or more of the four examined components.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.